# Ivabradine in the Acute Management of Cardiogenic Shock

Study · id `cardio:ct-nct07714746` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07714746](<https://clinicaltrials.gov/study/NCT07714746>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT07714746

Browse, organ or system: Heart  
Browse, condition area: Acute care and long-term living  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 200 participants.

## Technical summary

Registry record NCT07714746. Randomized; quadruple masking; primary purpose treatment. Start 2026-04-20 (actual); primary completion 2027-05-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 200 participants (planned count; ClinicalTrials.gov record NCT07714746, source copy `cardio:ctgov-nct07714746-2026-07-20`, retrieved 2026-10-31)
- Started: 2026-04-20 (actual) (ClinicalTrials.gov record NCT07714746, source copy `cardio:ctgov-nct07714746-2026-07-20`, retrieved 2026-10-31)
- Primary completion: 2027-05-31 (anticipated) (ClinicalTrials.gov record NCT07714746, source copy `cardio:ctgov-nct07714746-2026-07-20`, retrieved 2026-10-31)
- Completion: 2027-05-31 (anticipated) (ClinicalTrials.gov record NCT07714746, source copy `cardio:ctgov-nct07714746-2026-07-20`, retrieved 2026-10-31)
- Countries: Pakistan (ClinicalTrials.gov record NCT07714746, source copy `cardio:ctgov-nct07714746-2026-07-20`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07714746-2026-07-20`, retrieved 2026-10-31)

## The registry's words

- Brief title: Ivabradine in the Acute Management of Cardiogenic Shock
- Acronym: IVASHOCK
- Condition: Cardiogenic Shock Post Myocardial Infarction
- Intervention (Drug): Ivabradine 5mg Tab
- Intervention (Drug): Placebo Oral Tablet
- Lead sponsor: National Institute of Cardiovascular Diseases, Pakistan
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Cardiogenic shock (`cardio:cardiogenic-shock`)
- Registry lists this organization as the lead sponsor: National Institute of Cardiovascular Diseases, Pakistan (`cardio:org-national-institute-of-cardiovascular-diseases-pakistan`)

## Provenance

Content hash: 4a3aa95bfa5cf0f982f8852b4fe3f54acf157092ef13a34a0d53a3a2302755ce
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
